Gastric Neuroendocrine Tumor

Naresh Kargwal; Viraj Panda; Abhijeet Jha; Chandra Bhushan Singh

doi:10.1055/s-0041-1731427

The Surgery Journal, Table of Contents

CC BY 4.0 · Surg J (N Y) 2021; 07(03): e142-e146
DOI: 10.1055/s-0041-1731427

Case Report

Gastric Neuroendocrine Tumor

Authors

Naresh Kargwal

¹Department of General Surgery, Maulana Azad Medical College, New Delhi, India
Viraj Panda

¹Department of General Surgery, Maulana Azad Medical College, New Delhi, India
Abhijeet Jha

¹Department of General Surgery, Maulana Azad Medical College, New Delhi, India
Chandra Bhushan Singh

¹Department of General Surgery, Maulana Azad Medical College, New Delhi, India

Abstract

Gastric neuroendocrine tumor (gNET) is a rare carcinoid of the stomach whose incidence is increasing due to widespread use of upper gastrointestinal endoscopy (UGIE). There are four types of gNETs with different management strategies and prognosis. Here, we present a patient who came with abdomen pain and intermittent melena. UGIE showed a sessile polyp in the stomach. The patient subsequently underwent polypectomy and was symptomatically relieved.

Keywords

carcinoid - neuroendocrine - tumor - gastric

Full Text

References

References
1 Kwon DH, Nakakura EK, Bergsland EK, Dai SC. Gastric neuroendocrine tumors: management and challenges. Gastrointestinal Cancer: Targets and Therapy 2017; 29 (07) 31-37
2 Dias AR, Azevedo BC, Alban LBV. et al. Gastric neuroendocrine tumor: review and update. Arq Bras Cir Dig 2017; 30 (02) 150-154
3 Lupinacci RM, Dias AR, Mello ES, Kondo A. Minute type I gastric carcinoid with regional lymph node metastasis. Int J Surg Pathol 2013; 21 (02) 169-172
4 Fossmark R, Sørdal Ø, Jianu CS. et al. Treatment of gastric carcinoids type 1 with the gastrin receptor antagonist netazepide (YF476) results in regression of tumours and normalisation of serum chromogranin A. Aliment Pharmacol Ther 2012; 36 (11-12): 1067-1075
5 Nikou GC, Angelopoulos TP. Current concepts on gastric carcinoid tumors. Gastroenterol Res Pract 2012; 2012: 287825
6 Carmack SW, Genta RM, Schuler CM, Saboorian MH. The current spectrum of gastric polyps: a 1-year national study of over 120,000 patients. Am J Gastroenterol 2009; 104 (06) 1524-1532
7 Li TT, Qiu F, Qian ZR, Wan J, Qi XK, Wu BY. Classification, clinicopathologic features, and treatment of gastric neuroendocrine tumors. World J Gastroenterol 2014; 20 (01) 118-125
8 Namikawa T, Oki T, Kitagawa H, Okabayashi T, Kobayashi M, Hanazaki K. Neuroendocrine carcinoma of the stomach: clinicopathological and immunohistochemical evaluation. Med Mol Morphol 2013; 46 (01) 34-40
9 Gonzalez HH, Acosta M, Yazji G, Bromer MQ. Type 1 gastric neuroendocrine tumor found on endoscopic polypectomy. Cureus 2019; 11 (03) e4193
10 Grozinsky-Glasberg S, Kaltsas G, Gur C. et al. Long-acting somatostatin analogues are an effective treatment for type 1 gastric carcinoid tumours. Eur J Endocrinol 2008; 159 (04) 475-482
11 Gupta S, Johnson MM, Murthy R. et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer 2005; 104 (08) 1590-1602
12 Breeman WA, de Jong M, Kwekkeboom DJ. et al. Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations, and future perspectives. Eur J Nucl Med 2001; 28 (09) 1421-1429